Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans
Authors:
- 1 January 2008
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (1) , 53-59
Abstract
Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)‐dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate–induced platelet aggregation. This open‐label, multiple‐dose, 2‐period, fixed‐sequence study assessed CYP2B6 inhibition by prasugrel using bupropion as a probe substrate, where its active metabolite, hydroxybupropion, is almost exclusively formed by CYP2B6. Thirty healthy subjects received a single 150‐mg oral dose of sustained‐release bupropion. After a 7‐day washout, a 60‐mg prasugrel loading dose, followed by a 10‐mg daily maintenance dose for 10 days, was administered. Bupropion (150 mg) was given with prasugrel on day 7 of this phase. Prasugrel weakly inhibited CYP2B6 activity as it increased bupropion Cmaxand AUC0‐∞by 14% and 18%, respectively, and decreased hydroxybupropion Cmaxand AUC0‐∞by 32% and 23%. These results are consistent with patients receiving prasugrel not requiring dose adjustments when treated with drugs primarily metabolized by CYP2B6.Keywords
This publication has 19 references indexed in Scilit:
- The Disposition of Prasugrel, a Novel Thienopyridine, in HumansDrug Metabolism and Disposition, 2007
- A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationAmerican Heart Journal, 2007
- Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)American Heart Journal, 2006
- Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjectsBlood, 2006
- Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEuropean Heart Journal, 2006
- INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450Drug Metabolism and Disposition, 2006
- Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and TiclopidineThe Journal of Pharmacology and Experimental Therapeutics, 2004
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEDrug Metabolism and Disposition, 2003
- Ticlopidine as a Selective Mechanism-Based Inhibitor of Human Cytochrome P450 2C19Biochemistry, 2001
- The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBritish Journal of Pharmacology, 2000